Fisher Asset Management LLC Buys 188 Shares of Shockwave Medical, Inc. (NASDAQ:SWAV)

Fisher Asset Management LLC boosted its position in shares of Shockwave Medical, Inc. (NASDAQ:SWAV) by 0.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 75,849 shares of the company’s stock after purchasing an additional 188 shares during the period. Fisher Asset Management LLC owned about 0.21% of Shockwave Medical worth $14,454,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Lindbrook Capital LLC grew its holdings in shares of Shockwave Medical by 64.8% during the third quarter. Lindbrook Capital LLC now owns 150 shares of the company’s stock worth $30,000 after buying an additional 59 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Shockwave Medical by 297.4% in the third quarter. EverSource Wealth Advisors LLC now owns 155 shares of the company’s stock valued at $31,000 after purchasing an additional 116 shares during the last quarter. Asset Management One Co. Ltd. bought a new stake in shares of Shockwave Medical in the fourth quarter worth $34,000. Operose Advisors LLC acquired a new position in Shockwave Medical during the third quarter worth $49,000. Finally, Venturi Wealth Management LLC acquired a new position in Shockwave Medical during the third quarter worth $82,000. Institutional investors and hedge funds own 95.35% of the company’s stock.

Insiders Place Their Bets

In other news, VP Trinh Phung sold 599 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $259.24, for a total value of $155,284.76. Following the transaction, the vice president now owns 31,031 shares of the company’s stock, valued at $8,044,476.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Frank T. Watkins sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $231.76, for a total transaction of $463,520.00. Following the transaction, the director now directly owns 4,532 shares of the company’s stock, valued at $1,050,336.32. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Trinh Phung sold 599 shares of Shockwave Medical stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $259.24, for a total transaction of $155,284.76. Following the completion of the sale, the vice president now owns 31,031 shares of the company’s stock, valued at approximately $8,044,476.44. The disclosure for this sale can be found here. Insiders sold 86,407 shares of company stock worth $22,081,356 over the last three months. Insiders own 3.40% of the company’s stock.

Wall Street Analysts Forecast Growth

SWAV has been the topic of several analyst reports. Leerink Partnrs cut shares of Shockwave Medical from an “outperform” rating to a “market perform” rating in a research report on Friday, April 5th. TheStreet upgraded Shockwave Medical from a “c+” rating to a “b” rating in a report on Thursday, February 15th. CL King restated a “neutral” rating on shares of Shockwave Medical in a research note on Monday, April 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Shockwave Medical in a research report on Friday, April 5th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $335.00 price objective (up previously from $285.00) on shares of Shockwave Medical in a report on Monday, April 8th. Ten equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $309.11.

Shockwave Medical Stock Up 0.1 %

SWAV opened at $330.38 on Monday. The stock’s fifty day simple moving average is $301.64 and its 200 day simple moving average is $238.23. Shockwave Medical, Inc. has a 1-year low of $157.00 and a 1-year high of $331.58. The stock has a market cap of $12.39 billion, a PE ratio of 85.37, a price-to-earnings-growth ratio of 2.46 and a beta of 0.88. The company has a current ratio of 11.76, a quick ratio of 10.73 and a debt-to-equity ratio of 1.09.

Shockwave Medical (NASDAQ:SWAV) last issued its quarterly earnings data on Thursday, February 15th. The company reported $1.16 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.24. The company had revenue of $202.98 million for the quarter, compared to analyst estimates of $199.43 million. Shockwave Medical had a net margin of 20.17% and a return on equity of 23.97%. The company’s revenue was up 41.0% on a year-over-year basis. During the same period in the prior year, the firm earned $3.71 earnings per share. As a group, research analysts expect that Shockwave Medical, Inc. will post 4.94 earnings per share for the current year.

Shockwave Medical Company Profile

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.